Legend Biotech Corp(LEGN)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2025-12-31.

Legend Biotech Corp (LEGN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LEGN at 47.8/100 on a 32-signal composite quality model, placing it at rank #1,761 of 2,962 stocks — the bottom half of the AI-ranked universe. LEGN scores in the top quartile across revenue growth (96.5), institutional flow (86.1). Areas of concern include balance sheet strength (12.1) and profitability (13.6), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q3 2025), Legend Biotech Corp reports quarterly revenue of $272.4M, net income of $-39.7M. Top institutional holders of LEGN by reported 13-F value include FMR, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), SUVRETTA CAPITAL MANAGEMENT, based on the most recent SEC filings. LEGN trades on the Nasdaq exchange and files with the SEC under CIK 1801198. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LEGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Legend Biotech Corp directly from SEC EDGAR.